Preclinical News and Research

RSS

Study shows link between oral microbiome and naturally occurring alveolar bone loss

It is becoming increasingly clear that the human microbiome – the collection of bacteria, viruses and fungi that live on and within us – significantly contributes to our health.

17 Feb 2022

New METPlatform allows researchers to test drugs for possible use in brain metastases

It is estimated that about a quarter of cancer patients are at risk of brain metastases, a rate that is increasing especially among those who suffer relapses after having undergone different cancer treatments.

17 Feb 2022

Human nose organoids provide better understanding of the first steps toward SARS-CoV-2 infection

Preclinical models that recapitulate aspects of human airway disease are essential for the advancement of novel therapeutics and vaccines.

16 Feb 2022

Phase one study of oral SARS-CoV-2 antiviral agent nirmatrelvir

A recent study posted to the medRxiv* preprint server reported the phase one pharmacokinetic and safety data of nirmatrelvir/ritonavir to facilitate its rapid progression to the last stages of clinical trials in coronavirus disease 2019 (COVID-19) patients with mild to moderate disease.

14 Feb 2022

Discovery may lead to new treatment approach for people with alcohol-associated liver disease

Investigators at Cedars-Sinai have uncovered a new pathway that helps explain how consuming too much alcohol causes damage to the liver, specifically mitochondrial dysfunction in alcohol-associated liver disease.

14 Feb 2022

mRNA-1273 and mRNA-1273.529 Omicron-specific boosters highly effective in mouse model

In a study posted to the bioRxiv* preprint server, a team of researchers from the United States evaluated the protective effect of the preclinical version of the current Moderna Omicron-targeted mRNA-1273.529 vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.529 Omicron infection in mice.

14 Feb 2022

Nitazoxanide shows promise for COVID-19 treatment in animal model

In a recent study posted to the bioRxiv* pre-print server, researchers demonstrated that Nitazoxanide (NTZ), an oral drug, broadly inhibits replication of several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) in preclinical models of infection.

13 Feb 2022

Researchers shows how ΔNp63 protein contributes to lung cancer development

Lung cancer is the second most common cancer in the U.S. and the No. 1 cause of cancer related death. Despite considerable progress in treatment options, most lung cancer patients have extremely poor outcomes with an average five-year survival rate of 21.7%.

12 Feb 2022

Ketogenic diet could enhance the efficacy of chemotherapy for pancreatic cancer, study shows

A Ludwig Cancer Research preclinical study has demonstrated that a common weight-loss diet could enhance the efficacy of chemotherapy for pancreatic cancer.

12 Feb 2022

Alkem signs license agreement with Harvard to develop, commercialize new technology for treating ischemic conditions

Alkem Laboratories Limited, an Indian multinational pharmaceutical company, has signed a license agreement with Harvard University's Office of Technology Development enabling Alkem to develop and commercialize a novel technology that may help meet the dire need for effective treatment of diabetic neuropathy, foot ulcers, peripheral arterial disease (PAD), and other injuries caused by vascular disease.

11 Feb 2022

Simple eye test may help identify Alzheimer’s risk in middle age

A simple eye test may make diagnosing the earliest stages of 'diseases of old age' possible when people are much younger, University of Otago researchers hope.

10 Feb 2022

Properties and pharmacokinetics an oral drug candidate for COVID-19 treatment

Researchers studied the preclinical PK) and in vitro ADME properties of GS-441524, a potential oral drug for COVID-19 treatment.

10 Feb 2022

Study tests efficacy of molnupiravir against SARS-CoV-2 VOCs in various animal models

A study published on the bioRxiv* preprint server evaluates molnupiravir against a panel of relevant VOCs using three efficacy models: primary human airway epithelium organoids, a ferret model of upper respiratory disease, and a Roborovski dwarf hamster model for severe COVID-19.

9 Feb 2022

Old FDA-approved drug may protect against lung injury and blood clots in severe COVID-19

An FDA-approved drug that has been in clinical use for more than 70 years may protect against lung injury and the risk of blood clots in severe COVID-19 and other disorders that cause immune-mediated damage to the lungs, according to a preclinical study from researchers at Weill Cornell Medicine and Cold Spring Harbor Laboratory.

8 Feb 2022

Investigating taraxerol as a protease inhibitor against SARS-CoV-2

In a recent study posted to the Research Square preprint* server, a team of researchers investigated the toxicity and absorption, distribution, metabolism, and excretion (ADME) characteristics of a potent herbal drug, taraxerol, in the management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The paper is under consideration for publication in the Structural Chemistry journal.

7 Feb 2022

Potential tumor vulnerability may be exploited to improve treatment of neuroblastoma

A Ludwig Cancer Research study has identified a potential vulnerability in neuroblastoma tumors that might be exploited to improve treatment of the aggressive childhood cancer, which accounts for roughly 15% of all deaths from pediatric malignancies.

7 Feb 2022

Researchers develop 3D human spinal cord implants for treating paralyzed patients

For the first time in the world, researchers from Sagol Center for Regenerative Biotechnology at Tel Aviv University have engineered 3D human spinal cord tissues and implanted them in lab model with long-term chronic paralysis.

7 Feb 2022

Study investigates if prior SARS-CoV-2 infection increases sensitivity to toxin that induces parkinsonism

A recent study explored whether individuals who have recovered from mild to moderate or severe COVID-19 may have an increased risk for developing Parkinson’s disease in the future.

7 Feb 2022

Cerebrovascular impairment persists months after severe acute COVID-19, UK study

Researchers in the United Kingdom have conducted an observational cohort study on hospitalized patients and have found that the degree of severity of acute coronavirus disease 2019 (COVID-19) predicts the occurrence of chronic cerebrovascular impairment. The study further suggests that the levels of cerebrovascular impairment are associated with worse cognitive, mental, and physical well-being.

7 Feb 2022

Researchers develop influenza virus-like particle-based hybrid vaccine for both influenza and SARS-CoV-2 viruses

In a new study, a team of researchers developed a hybrid vaccine for SARS-CoV-2 and influenza viruses using influenza virus-like particles (VLP).

4 Feb 2022

Preclinical News and Research

Study shows link between oral microbiome and naturally occurring alveolar bone loss

New METPlatform allows researchers to test drugs for possible use in brain metastases

Human nose organoids provide better understanding of the first steps toward SARS-CoV-2 infection

Phase one study of oral SARS-CoV-2 antiviral agent nirmatrelvir

Discovery may lead to new treatment approach for people with alcohol-associated liver disease

mRNA-1273 and mRNA-1273.529 Omicron-specific boosters highly effective in mouse model

Nitazoxanide shows promise for COVID-19 treatment in animal model

Researchers shows how ΔNp63 protein contributes to lung cancer development

Ketogenic diet could enhance the efficacy of chemotherapy for pancreatic cancer, study shows

Alkem signs license agreement with Harvard to develop, commercialize new technology for treating ischemic conditions

Simple eye test may help identify Alzheimer’s risk in middle age

Properties and pharmacokinetics an oral drug candidate for COVID-19 treatment

Study tests efficacy of molnupiravir against SARS-CoV-2 VOCs in various animal models

Old FDA-approved drug may protect against lung injury and blood clots in severe COVID-19

Investigating taraxerol as a protease inhibitor against SARS-CoV-2

Potential tumor vulnerability may be exploited to improve treatment of neuroblastoma

Researchers develop 3D human spinal cord implants for treating paralyzed patients

Study investigates if prior SARS-CoV-2 infection increases sensitivity to toxin that induces parkinsonism

Cerebrovascular impairment persists months after severe acute COVID-19, UK study

Researchers develop influenza virus-like particle-based hybrid vaccine for both influenza and SARS-CoV-2 viruses

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics